drugset / Trial / NCT00447564

Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence

NCT00447564

Phase 3 Completed 163 enrolled Titan Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

Buprenorphine (BPN) is an approved treatment for opioid dependence, however, in taking oral tablets, patients experience withdrawal and cravings when the variable BPN levels in the blood are low. Probuphine is an implant placed just beneath the skin that contains BPN. It is designed to provide 6 months of stable BPN blood levels. This study will test the safety and efficacy of Probuphine in the treatment of patients with opioid dependence.

Timeline

Start
2006-10
Primary completion
2008-07
Completion
2008-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Buprenorphine Other / unclassified 80 mg Subcutaneous

Indications